amelparib (JPI-289) / Jeil, Oncocross 
Welcome,         Profile    Billing    Logout  
 5 Diseases   0 Trials   0 Trials   17 News 
  • ||||||||||  amelparib (JPI-289) / Jeil
    Effects of Delayed Treatment With Poly (ADP-Ribose) Polymerase Inhibitor After Ischemia-Reperfusion on Healing Phase of Renal Injury (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1004;    
    JPI-289 treatment of 0.5 and 0.75 mg/mL at 3 or 6 hours after hypoxia facilitated the proliferation of hypoxic HK-2 cells, whereas further treatment after 24 hours suppressed proliferation even with lower dosages. Conclusion Our results suggest that late treatment of PARP inhibitors after renal IRI did not have a beneficial effect on the recovery of ischemic AKI, but rather could have a negative effect on healing.
  • ||||||||||  amelparib (JPI-289) / Jeil
    [VIRTUAL] Poly (ADP-Ribose) Polymerase Inhibitor Treatment Attenuated Renal Ischemia-Reperfusion Injury (Virtual) -  May 29, 2020 - Abstract #ATC2020ATC_1547;    
    PARP inhibition with JPI-289 treatment showed favorable effects in ischemic AKI by attenuating intrarenal inflammatory cascade in a murine model and facilitating proliferation of hypoxic HK-2 cells. JPI-289 treatment mitigated renal injury by changing intrarenal immunologic micromilieu favorably in a murine ischemic AKI model and restored proliferation of HK-2 cells after hypoxia.
  • ||||||||||  amelparib (JPI-289) / Jeil, Oncocross
    Trial completion date, Trial primary completion date:  Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke (clinicaltrials.gov) -  Nov 18, 2019   
    P2a,  N=110, Recruiting, 
    JPI-289 treatment mitigated renal injury by changing intrarenal immunologic micromilieu favorably in a murine ischemic AKI model and restored proliferation of HK-2 cells after hypoxia. Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2020
  • ||||||||||  amelparib (JPI-289) / Jeil
    The Effects of PARP Inhibitor Treatment on Early Renal Injury in a Murine Ischemic AKI Model (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_3621;    
    Conclusion JPI-289 treatment attenuated early renal injury in a murine ischemic AKI model and facilitated proliferation of hypoxic HK-2 cells. Further studies are needed to identify optimal dosage and administration timing of JPI-289 treatment.